Preliminary Clinical Evaluation ViraMedX
In an initial, preclinical study conducted 4/1989-9/1989, to
determine the effectiveness of Viracea (ViraMedx®) on herpes, seven
human test subjects who had been tested positive for HSV 1 or 2, were
treated topically with the composition. Application of the composition
was made by first wetting the affected area or vesicle with the diluted
compound 1 by either spraying, dabbing, or by using a dropper; then
applying a coating of compound 2 over the wetted area by either swab or
manually sprinkling the botanical powder onto the area. An important
aspect in this treatment was maintaining complete coverage of the
affected area for the duration of the outbreak. Therefore, the area of
outbreak was kept covered with the composition by reapplying as needed.
Of the seven subjects, 6 were female , and 1 was male. At the
beginning of this study, the age of the male was 38, the female subjects
were ages 8, 27, 30, 32, 38, and 39. There were twelve infectious
outbreaks over approximately six weeks. Nine of the outbreaks were HSV
2, genital herpes, and three were HSV 1, cold sores. The 8 year old and
the 27 year old females exhibited the HSV 1 (cold sores). The 30 year
old, 38 year old and the 39 year old females exhibited the HSV 2
(genital herpes). The 38 year old also had a HSV 1 cold sore. The male
exhibited HSV 2 (genital herpes). All subjects tested had a well
established history of the disease and could identify the standard
course of their disease. To obtain objective data, none of the test
subjects knew anything about the treatment or any action of the
invention and on repeat tests, subjects were told that there may be
placebos mixed in the samples of formula.
In seven cases the compound was applied directly on tissue at the
prodrome stage. In five cases the compound was applied on erupted
vesicles. The compound was reapplied as necessary to maintain coverage
Observations
With each application, each individual reported a tingling sensation
for a few seconds. They also reported that there was a substantial
degree of adherence of the compound to the vesicle(s) or affected area.
The adherence of the composition to the epithelial tissue remained to a
degree even after showering or water rinsing the area.
Results
The results were surprisingly good and very consistent. In each case
the subject happily reported that once the composition was applied to
the affected area, the pain completely stopped within ten to twenty
minutes when nothing in the past had ever eased pain before.
In the seven cases where the compound was applied at the prodrome
stage, the subjects reported that the pain stopped, all symptoms that
would have previously escalated to full outbreak ceased and the outbreak
never occurred. All symptoms disappeared within a few hours.
In the cases where the compound was applied to erupted vesicles, the
subjects reported that the pain stopped in minutes and the burning,
itching and irritation resolved in two to four hours and the vesicles
dried up and were gone in twenty-one hours.
In all cases, the other more extreme, debilitating symptoms of:
fever, malaise, inguinal swelling, weeping sores and painful urination
never occurred.
In follow-up study, 1989 - present where subjects had been given a
supply of the composition to test on future outbreaks, it was reported
that if the initial signs of an outbreak exhibited, signaling the
prodrome stage of an outbreak, the compound was immediately applied and
the outbreak was fully arrested and did not occur. It was also oddly
reported by subjects who were accustomed to experiencing several
outbreaks annually, that they had remarkably longer latency periods. In
a three year follow-up with one individual who had reported severe
outbreaks monthly for four years prior to use of this invention, she now
reports that she has not had an outbreak in over 3 years since using
this product.
Additional Observations
One human male subject reported that after the initial application
during the prodrome phase of an outbreak, he showered and forgot to
reapply the composition for a period of approximately thirty hours.
Consequently, several vesicles erupted and began to coalesce. The
subject proceeded to reapply the composition and thereafter kept the
area well coated with the composition. Subsequently, the outbreak
resolved in twenty-one hours in the same manner as described with the
other human subjects.
Another observation indicated that the composition is weakened or may
be less effective in the presence of certain proteins or soaps. One
human female subject, may have been overly zealous in cleansing the
affected area prior to application of the composition. This occurred
during a third outbreak after having success with the composition on the
two prior outbreaks. In this instance, when the composition was applied,
there was no familiar tingling sensation and no relief from symptoms.
Approximately twenty-four hours elapsed before she sought any advice and
the outbreak had escalated to the full vesicular eruption stage with all
the foregoing symptoms of the disease. She was instructed to thoroughly
rinse any soap residue from the area, dry the area and reapply the
composition. After following the instructions, she reported that the
outbreak fully resolved, as it had in the two prior outbreaks, by the
medical composition.
